Association between carotenoid intake and metabolic dysfunction-associated fatty liver disease among US adults: A cross-sectional study

被引:4
作者
Zhang, Hang [1 ]
Li, Li [2 ]
Jia, Lei [3 ]
Liu, Jinchun [4 ]
机构
[1] Shanxi Med Univ, Clin Med Coll 1, Taiyuan, Peoples R China
[2] Tianjin Med Univ, Hosp 2, Intens Care Unit, Tianjin, Peoples R China
[3] Chinese Acad Med Sci & Peking Union Med Coll, Inst Hematol & Blood Dis Hosp, Tianjin, Peoples R China
[4] Shanxi Med Univ, Hosp 1, Dept Gastroenterol, Taiyuan 030001, Peoples R China
关键词
carotenoids; MAFLD; lycopene; hepatic steatosis; NHANES; DIETARY-INTAKE; INFLAMMATION; METAANALYSIS; ZEAXANTHIN; DIAGNOSIS; FIBROSIS; SOCIETY; LUTEIN; RISK;
D O I
10.1097/MD.0000000000036658
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Carotenoids have been recognized for their potential health benefits due to their antioxidant properties. There is limited research on the association between metabolic dysfunction-associated fatty liver disease (MAFLD) and carotenoids. This study aimed to investigate the effect of carotenoid intake on the risk of MAFLD. We retrospectively analyzed 2722 adults aged >= 18 from the National Health and Nutrition Examination Survey 2017-2018. Hepatic steatosis was identified by elastography, and carotenoid consumption was evaluated through two 24-hour dietary recall interviews. Weighted logistic regression models, subgroup analyses, and restricted cubic splines were used for analyses. The weighted prevalence of MAFLD was 51.90%. Weighted logistic regression analysis demonstrated that intake of beta-carotene, lutein/zeaxanthin, and lycopene was associated with a lower risk of MAFLD after adjusting for various covariates. Compared to the lowest tertile, a significant inverse correlation was observed between the highest total lycopene intake and MAFLD among females in the gender subgroup analysis. Restricted cubic spline regression analysis revealed a U-shaped association between lycopene consumption and MAFLD risk (P < .001), with an inflection point of approximately 9.48 mg/day. Moreover, the nonlinear relationship was particularly significant in females and absent in males. In summary, increased beta-carotene, lutein/zeaxanthin, and lycopene consumption was associated with a decreased risk of MAFLD. The relationship between total lycopene intake and MAFLD was nonlinear, primarily in females. These findings have significant implications for the potential prevention and management of MAFLD.
引用
收藏
页数:9
相关论文
共 50 条
[41]   Healthy dietary patterns and metabolic dysfunction-associated fatty liver disease in less-developed ethnic minority regions: a large cross-sectional study [J].
Xie, Xiaofen ;
Guo, Bing ;
Xiao, Xiong ;
Yin, Jianzhong ;
Wang, Ziyun ;
Jiang, Xiaoman ;
Li, Jingzhong ;
Long, Lu ;
Zhou, Junmin ;
Zhang, Ning ;
Zhang, Yuan ;
Chen, Ting ;
Kangzhuo, Baima ;
Zhao, Xing .
BMC PUBLIC HEALTH, 2022, 22 (01)
[42]   A Cross-sectional Real-life Study of the Prevalence, Severity, and Determinants of Metabolic Dysfunction-associated Fatty Liver Disease in Type 2 Diabetes Patients [J].
Binet, Quentin ;
Loumaye, Audrey ;
Hermans, Michel P. ;
Lanthier, Nicolas .
JOURNAL OF CLINICAL AND TRANSLATIONAL HEPATOLOGY, 2023, 11 (06) :1377-1386
[43]   Association between blood heavy metal exposure levels and risk of metabolic dysfunction associated fatty liver disease in adults: 2015-2020 NHANES large cross-sectional study [J].
Tang, Song ;
Luo, Simin ;
Wu, Zhendong ;
Su, Jiandong .
FRONTIERS IN PUBLIC HEALTH, 2024, 12
[44]   Links between metabolic syndrome and metabolic dysfunction-associated fatty liver disease [J].
Lim, Soo ;
Kim, Jin-Wook ;
Targher, Giovanni .
TRENDS IN ENDOCRINOLOGY AND METABOLISM, 2021, 32 (07) :500-514
[45]   Metabolic dysfunction-associated fatty liver disease and liver function markers are associated with Crohn's disease but not Ulcerative Colitis: a prospective cohort study [J].
Chen, Jie ;
Dan, Lintao ;
Tu, Xinru ;
Sun, Yuhao ;
Deng, Minzi ;
Chen, Xuejie ;
Hesketh, Therese ;
Li, Ran ;
Wang, Xiaoyan ;
Li, Xue .
HEPATOLOGY INTERNATIONAL, 2023, 17 (01) :202-214
[46]   Metabolic dysfunction-associated fatty liver disease: a year in review [J].
Alharthi, Jawaher ;
Gastaldelli, Amalia ;
Cua, Ian Homer ;
Ghazinian, Hasmik ;
Eslam, Mohammed .
CURRENT OPINION IN GASTROENTEROLOGY, 2022, 38 (03) :251-260
[47]   Prevalence of metabolic dysfunction-associated steatotic liver disease in inflammatory bowel disease patients: an Egyptian cross-sectional study [J].
Kamel, Shimaa Y. ;
Amin Sakr, Mohamed ;
Hamed, Waleed ;
Farid, Hoda M. ;
Alaa El-Din, Amr ;
Anwar, Ismail ;
Shehab, Hany ;
Omran, Salma ;
Sherif, Mirella ;
Negm, Mohamed ;
Bahig Elmihi, Nouran M. ;
Fathy, Dina .
EGYPTIAN JOURNAL OF INTERNAL MEDICINE, 2025, 37 (01)
[48]   Ferroptosis and metabolic dysfunction-associated fatty liver disease: Is there a link? [J].
Feng, Gong ;
Byrne, Christopher D. ;
Targher, Giovanni ;
Wang, Fudi ;
Zheng, Ming-Hua .
LIVER INTERNATIONAL, 2022, 42 (07) :1496-1502
[49]   Therapeutics for Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD) [J].
Bhopale, Kamlesh K. ;
Srinivasan, Mukund P. .
LIVERS, 2023, 3 (04) :597-617
[50]   Therapeutic developments in metabolic dysfunction-associated fatty liver disease [J].
Shi, Yiwen ;
Fan, Jiangao .
CHINESE MEDICAL JOURNAL, 2022, 135 (09) :1009-1018